Literature DB >> 15686736

Cicloral versus neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral.

F Kees1, G Mair, M Dittmar, M Bucher.   

Abstract

The bioavailability of cyclosporine a (CyA) was assessed in 2 cross-over studies with 12 healthy male volunteers each. Study A compared the bioavailability of Cicloral (test) with the microemulsion Neoral (reference) in the fasting state. Study B examined the influence of a fat-rich meal composed according to the Food and Drug Administration (FDA) recommendations on the bioavailability of Cicloral. Each volunteer received a single dose of 200 mg CyA in each period. Whole blood CyA concentrations were determined using HPLC up to 48 hours after drug administration. The pharmacokinetic parameters were determined using standard noncompartmental methods. The mean bioavailability of Cicloral compared with Neoral amounted to 83% (AUC) and 78% (Cmax), respectively. When administered after a fat-rich meal, the bioavailability of Cicloral was 121% (AUC) and 132% (Cmax) compared with fasting administration. Time to Cmax was 1.3 to 1.4 hours for both medications and modes of administration. Bioequivalence could not be proven either between Cicloral and Neoral, or between Cicloral fasting versus after a fat-rich meal. We conclude that the lower bioavailability and the influence of food on the bioavailability of Cicloral must be taken into account when switching from Neoral to the generic formulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15686736     DOI: 10.1016/j.transproceed.2004.10.018

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Neoimmun versus Neoral: a bioequivalence study in healthy volunteers and influence of a fat-rich meal on the bioavailability of Neoimmun.

Authors:  F Kees; M Bucher; F Schweda; H Gschaidmeier; L Faerber; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-15       Impact factor: 3.195

2.  Clinical evaluation of efficacy and safety of cyclosporine (Imusporin) in renal transplant patients with stable graft function maintained on neoral or bioral.

Authors:  Mrigank S Jha; Aneesh Srivastava; Deepak Dubey; Amit Gupta; R K Sharma; Anant Kumar
Journal:  Indian J Urol       Date:  2007-04

Review 3.  Bioavailability, Efficacy and Safety of Generic Immunosuppressive Drugs for Kidney Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Evangelos Tsipotis; Navin R Gupta; Gowri Raman; Elias Zintzaras; Bertrand L Jaber
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 4.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.